EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis

Journal of Pathology

Volumn 232, Issue 3, 2014, Pages 308-318

  Zhang, Pingyu ^a   Garnett, Jeannine ^a   Creighton, Chad J ^a,b   Al Sannaa, Ghadah Abbas ^a   Igram, Davis R ^a   Lazar, Alexander ^a   Liu, Xiuping ^a   Liu, Changgong ^a   Pollock, Raphael E ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

EZH2; KPNB1; miR 30d; MPNST; tumourigenesis

Indexed keywords

KARYOPHERIN BETA; KARYOPHERIN BETA 1; MICRORNA; MICRORNA 30D; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN RNA BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION TERMINATION; UPREGULATION;

EID: 84892379559     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4294     Document Type: Article

References (28)

1. Katz D, Lazar A, Lev D,. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med 2009; 11: e30.
2. Widemann BC,. Current status of sporadic and neurofi bromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep 2009; 11: 322-328.
3. Zou C, Smith KD, Liu J, et al., Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 2009; 249 (6): 1014-1022.
4. Anghileri M, Miceli R, Fiore M, et al., Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006; 107 (5): 1065-1074.
5. Tucker T, Wolkenstein P, Revuz J, et al., Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 2005; 65 (2): 205-211.
6. Kissil JL, Blakeley JO, Ferner RE, et al., What's new in neurofibromatosis? Proceedings from the 2009 NF conference: new frontiers. Am J Med Genet A 2010; 152A (2): 269-283.
7. Zou CY, Smith KD, Zhu Q-S, et al., Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Therap 2009; 8 (5): 1157-1168.
8. Lopez G, Torres K, Liu J, et al., Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res 2011; 71 (1): 185-196.
9. Johansson G, Mahller YY, Collins MH, et al., Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther 2008; 7 (5): 1237-1245.
10. Torres KE, Zhu Q-S, Bill K, et al., Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 2011; 17 (12): 3943-3955.
11. Zheng H, Chang L, Patel N, et al., Induction of abnormal proliferation by nonmyelinating Schwann cells triggers neurofibroma formation. Cancer Cell 2008; 13 (2): 117-128.
12. Wu J, Williams JP, Rizvi TA, et al., Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 2008; 13 (2): 105-116.
13. Cao R, Zhang Y,. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14 (2): 155-164.
14. Simon J, Lange C,. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21-29.
15. Simon JA, Lange CA,. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647 (1-2): 21-29.
16. Chen H, Gu X, Liu Y, et al., PDGF signalling controls age-dependent proliferation in pancreatic (bgr)-cells. Nature 2011; 478 (7369): 349-355.
17. Crea F, Fornaro L, Bocci G, et al., EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metast Rev 2012; 31 (3-4): 753-761.
18. Chang CJ, Hung MC,. The role of EZH2 in tumour progression. Br J Cancer 2012; 106 (2): 243-247.
19. Zhang X, Zhao X, Fiskus W, et al., Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B cell lymphomas. Cancer Cell 2012; 22 (4): 506-523.
20. Cao Q, Mani R-S, Ateeq B, et al., Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 2011; 20 (2): 187-199.
21. Zhang P, Bill K, Liu J, et al., MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling. Cancer Res 2012; 72 (7): 1751-1762.
22. Liu C-G, Calin GA, Volinia S, et al., MicroRNA expression profiling using microarrays. Nat Protoc 2008; 3 (4): 563-578.
23. Subramanian S, Thayanithy V, West RB, et al., Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol 2010; 220 (1): 58-70.
24. van der Watt PJ, Maske CP, Hendricks DT, et al., The Karyopherin proteins, Crm1 and Karyopherin-β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 2009; 124 (8): 1829-1840.
25. Terry LJ, Shows EB, Wente SR,. Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport. Science 2007; 318 (5855): 1412-1416.
26. Ciarapica R, Miele L, Giordano A, et al., Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications. BMC Med 2011; 9 (1): 63.
27. Strom AC, Weis K,. Importin-β-like nuclear transport receptors. Genome Biol 2001; 2 (6): reviews 3008.
28. Poon IK, Jans DA,. Regulation of nuclear transport: central role in development and transformation? Traffic 2005; 6 (3): 173-186.